Study Reveals Long-Term Benefits of Disease-Modifying Therapies for MS

Understanding Multiple Sclerosis

Multiple Sclerosis (MS) is one of the leading neurological causes of long-term disability. Although the exact cause of MS remains unknown, it typically affects the optic nerve, brainstem, cerebellum, and spinal cord. Symptoms can include weakness or loss of control of limbs, visual impairments, and sensory issues such as tingling sensations in the spine or limbs. While there is currently no cure, Disease-Modifying Therapies (DMT) such as interferon-beta-1a/1b, glatiramer acetate, dimethyl fumarate, and teriflunomide have emerged as effective treatments. These therapies not only reduce the frequency of relapses but also slow the disease’s progression, proving to be a cost-effective option in the long run.

Initial Costs vs. Long-Term Savings

Despite the initial financial burden associated with DMTs, recent evidence suggests that these therapies can ultimately lead to reduced healthcare resource utilization over time. A recent study published in BMJ Open explored the cost-effectiveness of DMTs among MS patients in Saskatchewan, Canada. The researchers analyzed data from the Discharge Abstract Database, covering the years from January 1997 to December 2016, to assess healthcare utilization in MS patients compared to the general population.

Study Findings

The study tracked the number of DMT dispensations annually, totaling 159,396 from 1997 to 2016. Throughout this period, the incidence of MS remained stable. Notably, hospitalization rates within the MS cohort decreased from 32,311 per 100,000 in 1997 to 16,544 per 100,000 in 2016. In contrast, the general public saw a reduction in all-cause hospitalization rates, from 14,240 per 100,000 in 1997 to 9,935 per 100,000 in 2016.

Regarding the average length of hospital stays, both the general public and the MS group showed similar patterns. However, the study highlighted a significant decline in MS-specific physician claims, which fell from 6.8 per person in 1997 to 3.5 per person in 2016 for those receiving DMTs.

Conclusion

The findings suggest that while Disease-Modifying Therapies represent a significant upfront investment, they can lead to substantial long-term reductions in healthcare costs and resource utilization for MS treatment. This indicates that DMTs may be a viable long-term strategy for managing Multiple Sclerosis effectively.

References

Al-Sakran, L., et al. (2019). BMJ Open. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
Edwards, C., et al. (2019). Davidson’s Principles and Practice of Medicine. 17th London, England: Pearson Professional Limited, 1996.
Image by Peggy und Marco Lachmann-Anke from Pixabay.